LIVE EVERY BREATH With GSK at ERS INTERNATIONAL CONGRESS 2018
PARIS France, 15-19 September
Visit GSK (H.02 and C.02) to find out about GSK’s innovative science. Also, attend our four ERS symposia and participate in our daily lunchtime forum discussions with GSK experts to discover how we are relentless in our pursuit to enable patients to live every breath.
Not going to ERS? Register for webcasts of our symposia, and see our daily highlights.
DAILY HIGHLIGHTS LIVE WEBCASTS
SCHEDULE OF EVENTS
Sun 16 Sept
Evening Symposium Effectiveness in everyday clinical practice:
New data from the Salford Lung Study in asthma
Register for webcast 17:15 — 19:15 Register for webcast
Respiratory Forum at GSK stand
12:45 — 14:45
Sun 16 Sept
Evening Symposium Effectiveness in everyday clinical practice:
New data from the Salford Lung Study in asthma
Register for webcast
Sept 16 17:15 — 19:15 Hall 7.3, Room Q
Register for webcast
Key Speakers

Professor Frédéric de Blay

University Hospital of Strasbourg, France

Professor Fabiano Di Marco

University of Milan, Italy

Dr Dave Leather

Global Respiratory Franchise, GSK, UK

Professor Mike Thomas

University of Southampton, UK
Timing
Effectiveness in everyday clinical practice:
New data from the Salford Lung Study in asthma
Speaker
17:15 — 17:20
Chair’s welcome.
Prof. Frederic De Blay
17:20 — 17:50
What does the evidence around RCTs in asthma tell us?
Prof. Fabiano Di Marco
17:50 — 18:20
The Salford Lung Study: defining effectiveness in every day clinical practice.
Dr. Dave Leather
18:20 — 18:50
The Salford Lung Study in context: a paradigm shift in assessing asthma therapies.
Prof. Mike Thomas
18:50 — 19:15
Q&A and closing remarks.
Prof. Frederic De Blay
17:15 — 17:20
Prof. Frederic De Blay
Chair’s welcome.
17:20 — 17:50
Prof. Fabiano Di Marco
What does the evidence around RCTs in asthma tell us?
17:50 — 18:20
Dr. Dave Leather
The Salford Lung Study: defining effectiveness in every day clinical practice.
18:20 — 18:50
Prof. Mike Thomas
The Salford Lung Study in context: a paradigm shift in assessing asthma therapies.
18:50 — 19:15
Prof. Frederic De Blay
Q&A and closing remarks.
Description
During this symposium, we will look at clinical effectiveness trials in practice, the features of a medicine that may impact effectiveness and how such trials impact treatment decisions. Our discussions will be focused around the design, implementation and results of the Salford Lung Study.
Respiratory Forum
Discuss the latest key areas of interest with GSK global medical experts, live on our commercial stand.
Questions
Time
Speaker
Should Triple Therapy be recommended as the preferred treatment choice for COPD patients after their first exacerbation?
12:45pm
Professor Paul Jones
Evolving evidence to support patients achieving asthma control
1:15pm
Dr Richard Tomiak
Who is the right patient for a biologic & when should we start them?
2:00pm
Professor Neil Barnes
12:45pm
Professor Paul Jones
Should Triple Therapy be recommended as the preferred treatment choice for COPD patients after their first exacerbation?
1:15pm
Dr. Richard Tomiak
Evolving evidence to support patients achieving asthma control
2:00pm
Professor Neil Barnes
Who is the right patient for a biologic & when should we start them?
Mon 17 Sept
Early Morning Symposium Patients as partners in drug development:
from rhetoric into reality
Register for webcast 07:00 — 08:15 Register for webcast
Evening Symposium Current COPD treatment paradigm and evidence:
what are the unanswered questions and the
clinical implications?
Register for webcast 17:15 — 19:15 Register for webcast
Respiratory Forum at GSK stand
12:45 — 14:45
Mon 17 Sept
Early Morning Symposium Patients as partners in drug development:
from rhetoric into reality
Register for webcast
Sept 17 07:00 — 08:15 Hall 7.3, Room R
Register for webcast
Key Speakers

Monica Fletcher OBE

Global Respiratory Franchise, GSK, UK

Kjeld Hansen

Patient advocate, Denmark

Dr Felix Jackson

Founder and Medical Director of medDigital and medCrowd, UK

Dr Ruth Tal-Singer

Respiratory R&D, GSK, USA

Dr Dave Leather

Global Respiratory Franchise, GSK, UK

Professor Alberto Papi

Timing
Patients as partners in drug development:
from rhetoric into reality
Speaker
07:00 — 07:05
Introduction/Welcome.
Monica Fletcher
07:05 — 07:15
What matters to me: A patient’s perspective.
Kjeld Hansen
07:15 — 07:25
Connecting with patients: The digital opportunity.
Dr. Felix Jackson
07:25 — 07:35
Technology to understand patients’ needs in clinical studies.
Dr. Ruth Tal-Singer
07:35 — 07:45
The Salford Lung Study in COPD: an opportunity for many more patients to take part in a clinical study.
Dr. Dave Leather
07:45 — 07:55
A patient-driven outcomes study: An Italian pilot.
Prof. Alberto Papi
07:55 — 08:10
The role of the patient in drug development.
Panel Discussion
08:10 — 08:15
Summary: From rhetoric into reality.
Monica Fletcher
07:00 — 07:05
Monica Fletcher
Introduction/Welcome.
07:05 — 07:15
Kjeld Hansen
What matters to me: A patient’s perspective.
07:15 — 07:25
Dr. Felix Jackson
Connecting with patients: The digital opportunity.
07:25 — 07:35
Dr. Ruth Tal-Singer
Technology to understand patients’ needs in clinical studies.
07:35 — 07:45
Dr. Dave Leather
The Salford Lung Study in COPD: an opportunity for many more patients to take part in a clinical study.
07:45 — 07:55
Prof. Alberto Papi
A patient-driven outcomes study: An Italian pilot.
07:55 — 08:10
Panel Discussion
The role of the patient in drug development.
08:10 — 08:15
Monica Fletcher
Summary: From rhetoric into reality.
Description
This symposium aims to give a broader understanding of the impact of respiratory diseases from a patient perspective. We want to explore ways of achieving a true partnership with patients in drug development by answering a number of key questions, such as:
  • Do we fully understand patient needs?
  • What do the terms ‘patient participation’ and ‘patient collaboration’ really mean?
  • How can we design clinical trials in collaboration with patients to define patient-reported outcomes and insights?
  • How can technological advancements and digital tools improve our partnership with patients?
Evening Symposium Current COPD treatment paradigm and evidence: what are the unanswered questions and the clinical implications?
Register for webcast
Sept 17 17:15 — 19:15 Hall 7.3, Room N
Register for webcast
Key Speakers

Professor Paul Jones

Global Respiratory Franchise, GSK, UK

Professor Bruno Housset

General Hospital of Créteil, France

Dr Henrik Watz

LungenClinic, Airway Research Center North, German Center for Lung Research, Germany

Dr David Lipson

Respiratory Research and Development, GSK, USA

Dr Alice Turner

Professor Neil Barnes

Timing
Current COPD treatment paradigm and evidence: what are
the unanswered questions and the clinical implications?
Speaker
17:15 — 17:20
Chairs’ welcome.
Chair: Prof. Paul Jones
Co Chair: Prof. Bruno Housset
17:20 — 17:35
Current COPD treatment paradigm: what does GOLD recommend and why?
Dr. Henrik Watz
17:35 — 17:50
Evidence from recent studies. The IMPACT study.
Dr. David Lipson
17:50 — 18:10
Approaches to bronchodilator treatment for the breathless patient.
Prof. Paul Jones
18:10 — 18:30
What to do with GOLD D patients?
Dr. Alice Turner
18:30 — 18:50
This patient had an exacerbation last year: what would you do?
Prof. Neil Barnes
18:50 — 19:15
Panel discussion and close.
Prof. Paul Jones and
Prof. Bruno Housset
17:15 — 17:20
Chair: Prof. Paul Jones
Co Chair: Prof. Bruno Housset
Chairs’ welcome.
17:20 — 17:35
Dr. Henrik Watz
Current COPD treatment paradigm: what does GOLD recommend and why?
17:35 — 17:50
Dr. David Lipson
Evidence from recent studies. The IMPACT study.
17:50 — 18:10
Prof. Paul Jones
Approaches to bronchodilator treatment for the breathless patient.
18:10 — 18:30
Dr. Alice Turner
What to do with GOLD D patients?
18:30 — 18:50
Prof. Neil Barnes
This patient had an exacerbation last year: what would you do?
18:50 — 19:15
Prof. Paul Jones and
Prof. Bruno Housset
Panel discussion and close.
Description
In this symposium, we shall review the current treatment recommendations for COPD, discuss the GOLD updates for 2018 and review recent clinical evidence. This will be followed by three interactive presentations of patient case studies, each examining how recent clinical trial evidence may shape future COPD treatment paradigms.
Respiratory Forum
Discuss the latest key areas of interest with GSK global medical experts, live on our commercial stand.
Questions
Time
Speaker
Will my patient lose response over time with Nucala (mepolizumab)?
12:45pm
Dr Frank Albers
Defining a necessary role for ICS in COPD
1:15pm
Professor Chris Cooper
Should LAMA/LABA treatment be the first line therapy for symptomatic COPD patients?
2:00pm
Professor Ronald Dahl
12:45pm
Dr. Frank Albers
Will my patient lose response over time with Nucala (mepolizumab)?
1:15pm
Prof. Chris Cooper
Defining a necessary role for ICS in COPD
2:00pm
Prof. Ronald Dahl
Should LAMA/LABA treatment be the first line therapy for symptomatic COPD patients?
Tues 18 Sept
Evening Symposium Anti-IL5 treatment options for the severe
eosinophilic asthma patient: Are they all the same?
Register for webcast 17:15 — 19:15 Register for webcast
Respiratory Forum at GSK stand
12:45 — 14:45
Tues 18 Sept
Evening Symposium Anti-IL5 treatment options for the severe
eosinophilic asthma patient: Are they all the same?
Register for webcast
Sept 18 17:15 — 19:15 Hall 7.3, Room M
Register for webcast
Key Speakers

Professor Marc Humbert

University of Paris-Saclay, France

Professor Peter Howarth

Global Respiratory Franchise, GSK, UK

Dr Brian Kent

Guy's and St Thomas' NHS Foundation Trust, UK

Professor Arnaud Bourdin

University of Montpellier, France

Dr Neil Martin

Timing
Anti-IL5 treatment options for the severe
eosinophilic asthma patient: are they all the same?
Speaker
17:15 — 17:30
Who is a candidate for anti-IL5 therapy?
Prof. Marc Humbert
17:30 — 17:50
Eosinophil functions and the role of IL-5.
Prof. Peter Howarth
17:50 — 18:15
What is the clinical benefit of using anti-IL5 in the severe eosinophilic asthma patient?
Dr. Brian Kent
18:15 — 18:35
What happens long term with IL-5 therapy?
Prof. Arnaud Bourdin
18:35 — 18:55
Start or stop? Strategy for patient selection.
Dr. Neil Martin
18:55 — 19:15
Q&A and Chair’s close: Are they all the same?
Prof. Marc Humbert
17:15 — 17:30
Prof. Marc Humbert
Who is a candidate for anti-IL5 therapy?
17:30 — 17:50
Prof. Peter Howarth
Eosinophil functions and the role of IL-5.
17:50 — 18:15
Dr. Brian Kent
What is the clinical benefit of using anti-IL5 in the severe eosinophilic asthma patient?
18:15 — 18:35
Prof. Arnaud Bourdin
What happens long term with IL-5 therapy?
18:35 — 18:55
Dr. Neil Martin
Start or stop? Strategy for patient selection.
18:55 — 19:15
Prof. Marc Humbert
Q&A and Chair’s close: Are they all the same?
Description
We begin this symposium with a summary of the function and effects of eosinophils. Then we will have an overview on anti-IL5 biologics focusing on current clinical data and patient eligibility criteria. Lastly, we will look at how we can assess response to biologics for severe asthma and what to consider before we start, continue or stop treatment.
Respiratory Forum
Discuss the latest key areas of interest with GSK global medical experts, live on our commercial stand.
Questions
Time
Speaker
Translating the IMPACT trial to clinical practice
12:45pm
Dr David Lipson
What can you do in an uncontrolled severe asthma patient with an overlapping phenotype?
1:15pm
Professor Peter Howarth
Discussing the benefit/risk of ICS in COPD
2:00pm
Professor Neil Barnes
12:45pm
Dr. David Lipson
Translating the IMPACT trial to clinical practice
1:15pm
Prof. Peter Howarth
What can you do in an uncontrolled severe asthma patient with an overlapping phenotype?
2:00pm
Prof. Neil Barnes
Discussing the benefit/risk of ICS in COPD
VISIT OUR STAND
This year, come and see how our unique approach to respiratory medicine is helping to improve the lives of patients everywhere.
COMMERCIAL STAND
RIGHT PATIENT, RIGHT TREATMENT
COMMERCIAL STAND

In this zone you will discover how our science and innovations are aimed at increasing disease understanding.

In this zone you will identify the appropriate patient for personalized treatment.

In this zone you will find out how our services and data aim to provide effectiveness for patients.

MEDICAL STAND
MEDICAL STAND

Discover how our innovative research is improving disease understanding and is being used to develop active and varied pipeline treatments.

Take a look at how we are working with healthcare professionals to help ensure that patients get the right treatment at the right time.

Find out how we are developing simple, practical ways to reduce exacerbations and improve patient outcomes.

Collect your ERS Abstracts USB here.

DAILY HIGHLIGHTS
View hightlights
DAY 1 HIGHLIGHTS Each day we will be recording the day's events and posting them here. Review what has been happening during the day at ERS or catch up on previous days' highlights.

UA Septiembre 2018: ESP/RESP/0155/18